

# Bengt Glimelius

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5000661/bengt-glimelius-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

301  
papers

21,634  
citations

61  
h-index

144  
g-index

324  
ext. papers

25,769  
ext. citations

5  
avg, IF

6.45  
L-index

#	Paper	IF	Citations
301	Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2102407	2.2	1
300	-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 826073	5.3	1
299	Current controversies in TNM for the radiological staging of rectal cancer and how to deal with them: results of a global online survey and multidisciplinary expert consensus.. <i>European Radiology</i> , <b>2022</b> , 1	8	2
298	The Immune Landscape of Colorectal Cancer. <i>Cancers</i> , <b>2021</b> , 13,	6.6	1
297	Multidisciplinary Treatment of Rectal Cancer <b>2021</b> , 163-178		
296	Survival trends of right- and left-sided colon cancer across four decades: a Norwegian population-based study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2021</b> ,	4	2
295	Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , <b>2021</b> ,	8.7	2
294	Interpreting the RAPIDO trial: factors to consider - Authors' reply. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, e90-e91.7	21.7	0
293	The prognostic impact of the tumour stroma fraction: A machine learning-based analysis in 16 human solid tumour types. <i>EBioMedicine</i> , <b>2021</b> , 65, 103269	8.8	8
292	Completeness and accuracy of the registration of recurrences in the Swedish Colorectal Cancer Registry (SCRCR) and an update of recurrence risk in colon cancer. <i>Acta Oncologica</i> , <b>2021</b> , 60, 842-849	3.2	4
291	Does exercise intensity matter for fatigue during (neo-)adjuvant cancer treatment? The Phys-Can randomized clinical trial. <i>Scandinavian Journal of Medicine and Science in Sports</i> , <b>2021</b> , 31, 1144-1159	4.6	9
290	Neoadjuvant rectal (NAR) score: Value evaluating the efficacy of neoadjuvant therapy and prognostic significance after surgery?. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 157, 70-77	5.3	2
289	Pretreatment MRI in Primary Rectal Cancer as a Predictor for Oncological Outcomes After Surgery for Local Recurrence. <i>Anticancer Research</i> , <b>2021</b> , 41, 2459-2465	2.3	
288	Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer. <i>International Journal of Cancer</i> , <b>2021</b> , 149, 1385-1397	7.5	1
287	Quality of Life in Vulnerable Older Patients with Metastatic Colorectal Cancer Receiving Palliative Chemotherapy-The Randomized NORDIC9-Study. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
286	Accurate population-based model for individual prediction of colon cancer recurrence. <i>Acta Oncologica</i> , <b>2021</b> , 60, 1241-1249	3.2	2
285	Quality of life assessments in clinical practice using either the EORTC-QLQ-C30 or the SEIQOL-DW: a randomized study. <i>Journal of Patient-Reported Outcomes</i> , <b>2021</b> , 5, 58	2.6	1

284	Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, <b>2021</b> , 22, 29-42	21.7	180
283	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. <i>Journal of Translational Genetics and Genomics</i> , <b>2021</b> , 5, 200-217	1.7	
282	Predictive Value of Neutrophils Count for Local Tumor Control After Chemoradiotherapy in Patients With Locally Advanced Pancreatic Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 110, 1022-1031	4	2
281	Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone. <i>Cancer Treatment Reviews</i> , <b>2021</b> , 98, 102218	14.4	7
280	Investigation of Relation of Radiation Therapy Quality With Toxicity and Survival in LAP07 Phase 3 Trial for Locally Advanced Pancreatic Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2021</b> , 110, 993-1002	4	2
279	Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis. <i>Clinical Colorectal Cancer</i> , <b>2021</b> , 20, 236-244	2.8	1
278	Prognostic Interactions between FAP+ Fibroblasts and CD8a+ T Cells in Colon Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	7
277	Adjuvant chemotherapy in rectal cancer: state of the art and future perspectives. <i>Current Opinion in Oncology</i> , <b>2020</b> , 32, 377-383	4.2	5
276	ASO Author Reflections: Emerging Risk Factors in Colon Cancer-End of the Line for Clinomics?. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 1046-1047	3.1	
275	CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better Mutated and a Worse Mutated Subgroup. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 8	5.3	13
274	Effects and moderators of coping skills training on symptoms of depression and anxiety in patients with cancer: Aggregate data and individual patient data meta-analyses. <i>Clinical Psychology Review</i> , <b>2020</b> , 80, 101882	10.8	2
273	Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 147, 75-83	5.3	62
272	Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4006-4006	2.2	67
271	ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: Five year follow-up.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4516-4516	2.2	6
270	Feasibility of switching to S-1 after other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 7037-7037	2.2	2
269	A Comprehensive Evaluation of Associations Between Routinely Collected Staging Information and The Response to (Chemo)Radiotherapy in Rectal Cancer. <i>Cancers</i> , <b>2020</b> , 13,	6.6	8
268	Evaluation of the antibody response to the EBV proteome in EBV-associated classical Hodgkin lymphoma. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 608-618	7.5	8
267	Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis. <i>Acta Oncologica</i> , <b>2020</b> , 59, 417-426	3.2	11

266	Beyond the NCCN Risk Factors in Colon Cancer: An Evaluation in a Swedish Population-Based Cohort. <i>Annals of Surgical Oncology</i> , <b>2020</b> , 27, 1036-1045	3.1	8
265	Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian study. <i>Acta Oncologica</i> , <b>2020</b> , 59, 284-290	3.2	3
264	Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version. <i>Acta Oncologica</i> , <b>2020</b> , 59, 1016-1023	3.2	2
263	Recurrence Risk after Radical Colorectal Cancer Surgery-Less Than before, But How High Is It?. <i>Cancers</i> , <b>2020</b> , 12,	6.6	8
262	O-19 Feasibility of switching to S-1 upon other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors. <i>Annals of Oncology</i> , <b>2020</b> , 31, 239	10.3	2
261	Adjuvant Chemotherapy in Elderly Colorectal Cancer Patients. <i>Cancers</i> , <b>2020</b> , 12,	6.6	4
260	Moderators of the effect of psychosocial interventions on fatigue in women with breast cancer and men with prostate cancer: Individual patient data meta-analyses. <i>Psycho-Oncology</i> , <b>2020</b> , 29, 1772-1785	3.9	5
259	Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. <i>International Journal of Cancer</i> , <b>2020</b> , 146, 94-102	7.5	15
258	No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. <i>British Journal of Haematology</i> , <b>2020</b> , 188, 685-691	4.5	10
257	International expert consensus statement regarding radiotherapy treatment options for rectal cancer during the COVID 19 pandemic. <i>Radiotherapy and Oncology</i> , <b>2020</b> , 148, 213-215	5.3	40
256	Postoperative complications in relation to overall treatment time in patients with rectal cancer receiving neoadjuvant radiotherapy. <i>British Journal of Surgery</i> , <b>2019</b> , 106, 1248-1256	5.3	12
255	Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients. <i>Cancer Medicine</i> , <b>2019</b> , 8, 3623-3635	4.8	23
254	Determining the use of preoperative (chemo)radiotherapy in primary rectal cancer according to national and international guidelines. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 136, 106-112	5.3	8
253	Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy. <i>Annals of Oncology</i> , <b>2019</b> , 30, 1088-1095	10.3	40
252	Lessons learned from the maturation of a cancer drug: oxaliplatin in colorectal cancer. <i>Acta Oncologica</i> , <b>2019</b> , 58, 395-397	3.2	1
251	Reduced-dose combination chemotherapy (S-1 plus oxaliplatin) versus full-dose monotherapy (S-1) in older vulnerable patients with metastatic colorectal cancer (NORDIC9): a randomised, open-label phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 376-388	18.8	20
250	Tumour regression after radiotherapy for rectal cancer - Results from the randomised Stockholm III trial. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 135, 178-186	5.3	44
249	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1539	5.3	1

248	Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes. <i>Genetic Epidemiology</i> , <b>2019</b> , 43, 844-863	2.6	15
247	Stroma-normalised vessel density predicts benefit from adjuvant fluorouracil-based chemotherapy in patients with stage II/III colon cancer. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 303-311	8.7	2
246	3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. <i>Health Technology Assessment</i> , <b>2019</b> , 23, 1-88	4.4	13
245	Surgical treatment and survival from colorectal cancer in Denmark, England, Norway, and Sweden: a population-based study. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 74-87	21.7	57
244	Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores. <i>Therapeutic Advances in Medical Oncology</i> , <b>2019</b> , 11, 1758835918818351	5.4	7
243	An audit of performance, interpretation, and influence of pretherapeutic MRI in rectal cancer: a Swedish population-based cohort study. <i>Acta Radiologica</i> , <b>2019</b> , 60, 955-961	2	1
242	The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , <b>2019</b> , 269, 520-529	7.8	127
241	Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 947-954	8.7	23
240	More than 1000 new manuscripts in 2017. <i>Acta Oncologica</i> , <b>2018</b> , 57, 174-175	3.2	0
239	Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, e151-e160	21.7	31
238	Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. <i>Blood</i> , <b>2018</b> , 131, 2541-2551	2.2	15
237	How Long to Wait After Preoperative Radio(Chemo) Therapy to Perform Surgery? <b>2018</b> , 463-474		
236	The PLIANT trial gives trustworthy data. <i>Acta Oncologica</i> , <b>2018</b> , 57, 864-866	3.2	1
235	Effects and moderators of psychosocial interventions on quality of life, and emotional and social function in patients with cancer: An individual patient data meta-analysis of 22 RCTs. <i>Psycho-Oncology</i> , <b>2018</b> , 27, 1150-1161	3.9	49
234	What treatments should be skipped or intensified in localized rectal cancer?. <i>Future Oncology</i> , <b>2018</b> , 14, 313-318	3.6	1
233	Short- and long-term risks of cardiovascular disease following radiotherapy in rectal cancer in four randomized controlled trials and a population-based register. <i>Radiotherapy and Oncology</i> , <b>2018</b> , 126, 424-430	5.3	6
232	Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. <i>European Journal of Cancer</i> , <b>2018</b> , 96, 115-124	7.5	1
231	3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 562-578	21.7	93

230	Quality of life and cost effectiveness in a randomized trial of patients with colorectal cancer and peritoneal metastases. <i>European Journal of Surgical Oncology</i> , <b>2018</b> , 44, 983-990	3.6	9
229	Intratumoural expression of deoxycytidylate deaminase or ribonucleotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1084-1088	8.7	5
228	U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden. <i>Acta Oncologica</i> , <b>2018</b> , 57, 187-194	3.2	32
227	Neoadjuvant Therapy in Rectal Cancer Patients With Clinical Stage II to III Across European Countries: Variations and Outcomes. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, e129-e142	3.8	15
226	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. <i>Cancer Research</i> , <b>2018</b> , 78, 4086-4096	10.1	18
225	Stage distribution utilizing magnetic resonance imaging in an unselected population of primary rectal cancers. <i>European Journal of Surgical Oncology</i> , <b>2018</b> , 44, 1858-1864	3.6	4
224	Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcome. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1609-1616	8.7	31
223	Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmagofodipir (PledOx): a placebo-controlled randomised phase II study (PLIANT). <i>Acta Oncologica</i> , <b>2018</b> , 57, 393-402	3.2	52
222	Treatment-related survival associations of claudin-2 expression in fibroblasts of colorectal cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2018</b> , 472, 395-405	5.1	5
221	Administration of adjuvant chemotherapy for stage II-III colon cancer patients: An European population-based study. <i>International Journal of Cancer</i> , <b>2018</b> , 142, 1480-1489	7.5	25
220	SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 1332-1338	8.7	9
219	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. <i>Nature Communications</i> , <b>2018</b> , 9, 4182	17.4	8
218	Recurrence Risk After Up-to-Date Colon Cancer Staging, Surgery, and Pathology: Analysis of the Entire Swedish Population. <i>Diseases of the Colon and Rectum</i> , <b>2018</b> , 61, 1016-1025	3.1	64
217	Preoperative radiotherapy or chemoradiotherapy in rectal cancer - Is survival improved? An update of the "Nordic" LARC study in non-resectable cancers. <i>Radiotherapy and Oncology</i> , <b>2018</b> , 127, 392-395	5.3	7
216	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , <b>2018</b> , 100, 35-45	7.5	20
215	Somatic Ephrin Receptor Mutations Are Associated with Metastasis in Primary Colorectal Cancer. <i>Cancer Research</i> , <b>2017</b> , 77, 1730-1740	10.1	16
214	Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 336-346	21.7	277
213	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. <i>Nature Communications</i> , <b>2017</b> , 8, 14175	17.4	54



212	On a prolonged interval between rectal cancer (chemo)radiotherapy and surgery. <i>Upsala Journal of Medical Sciences</i> , <b>2017</b> , 122, 1-10	2.8	21
211	Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study. <i>British Journal of Cancer</i> , <b>2017</b> , 116, 1271-1278	8.7	38
210	Need for adjuvant chemotherapy after colon cancer surgery - has it decreased?. <i>Acta Oncologica</i> , <b>2017</b> , 56, 629-633	3.2	5
209	Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status. <i>European Journal of Cancer</i> , <b>2017</b> , 81, 26-35	7.5	6
208	Development of anxiety, depression and health-related quality of life in oncology patients without initial symptoms according to the Hospital Anxiety and Depression Scale - a comparative study. <i>Acta Oncologica</i> , <b>2017</b> , 56, 1094-1102	3.2	8
207	Different functions of AKT1 and AKT2 in molecular pathways, cell migration and metabolism in colon cancer cells. <i>International Journal of Oncology</i> , <b>2017</b> , 50, 5-14	4.4	36
206	Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. <i>BMC Cancer</i> , <b>2017</b> , 17, 548	4.8	6
205	Prognostic factors in patients with loco-regionally advanced gastric cancer. <i>World Journal of Surgical Oncology</i> , <b>2017</b> , 15, 172	3.4	9
204	Reply to C.F. Hess et al. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 374	2.2	
203	Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer. <i>British Journal of Cancer</i> , <b>2017</b> , 117, 1478-1485	8.7	64
202	A pathology atlas of the human cancer transcriptome. <i>Science</i> , <b>2017</b> , 357,	33.3	1481
201	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , <b>2017</b> , 4, e000187	4.6	10
200	What conclusions can be drawn from the Stockholm III rectal cancer trial in the era of watch and wait?. <i>Acta Oncologica</i> , <b>2017</b> , 56, 1139-1142	3.2	9
199	Risk of second primary cancer in patients treated with radiotherapy for rectal cancer. <i>British Journal of Surgery</i> , <b>2017</b> , 104, 278-287	5.3	21
198	Associations of defect mismatch repair genes with prognosis and heredity in sporadic colorectal cancer. <i>European Journal of Surgical Oncology</i> , <b>2017</b> , 43, 311-321	3.6	10
197	High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. <i>PLoS ONE</i> , <b>2017</b> , 12, e0182512	3.7	14
196	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. <i>Carcinogenesis</i> , <b>2016</b> , 37, 852-7	4.6	13
195	Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). <i>British Journal of Cancer</i> , <b>2016</b> , 115, 281-9	8.7	48

194	Two countries - Two treatment strategies for rectal cancer. <i>Radiotherapy and Oncology</i> , <b>2016</b> , 121, 357-363	3.3	39
193	What is most relevant in preoperative rectal cancer chemoradiotherapy - the chemotherapy, the radiation dose or the timing to surgery?. <i>Acta Oncologica</i> , <b>2016</b> , 55, 1381-1385	3.2	7
192	ESPAC-4: A multicenter, international, open label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP), versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. <i>Pancreatology</i> , <b>2016</b> , 16, S63	3.8	19
191	Lymphovascular and perineural invasion in stage II rectal cancer: a report from the Swedish colorectal cancer registry. <i>Acta Oncologica</i> , <b>2016</b> , 55, 1418-1424	3.2	34
190	Tell all the good news as soon as possible. <i>Acta Oncologica</i> , <b>2016</b> , 55, 1067-1068	3.2	1
189	Image analysis-derived metrics of histomorphological complexity predicts prognosis and treatment response in stage II-III colon cancer. <i>Scientific Reports</i> , <b>2016</b> , 6, 36149	4.9	18
188	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. <i>Nature Communications</i> , <b>2016</b> , 7, 10933	17.4	70
187	Impact of pre-treatment patient-related selection parameters on outcome in rectal cancer. <i>European Journal of Surgical Oncology</i> , <b>2016</b> , 42, 1667-1673	3.6	7
186	Detection of Biomarkers with Solid-Phase Proximity Ligation Assay in Patients with Colorectal Cancer. <i>Translational Oncology</i> , <b>2016</b> , 9, 251-5	4.9	4
185	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. <i>Human Molecular Genetics</i> , <b>2016</b> , 25, 1663-76	5.6	39
184	Should the Benefit of Adjuvant Chemotherapy in Colon Cancer Be Re-Evaluated?. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 1297-9	2.2	44
183	Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial. <i>European Journal of Cancer</i> , <b>2016</b> , 53, 155-62	7.5	93
182	TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: a potential novel approach to the treatment of metastatic colorectal cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 59441-59457	3.3	5
181	Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 75013-75022	3.3	46
180	Survival-associated heterogeneity of marker-defined perivascular cells in colorectal cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 41948-41958	3.3	27
179	PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1557-65	10.3	47
178	Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 1844-53	27.4	538
177	Reply to D.J. Sargent et al. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3713-3714	2.2	



176	(15)O-Water PET Study of the Effect of Imatinib, a Selective Platelet-Derived Growth Factor Receptor Inhibitor, Versus Anakinra, an IL-1R Antagonist, on Water-Perfusible Tissue Fraction in Colorectal Cancer Metastases. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 1144-9	8.9	11
175	Is the benefit of oxaliplatin in rectal cancer clinically relevant?. <i>Lancet Oncology, The</i> , <b>2015</b> , 16, 883-5	21.7	6
174	Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: A meta-analysis of randomized trials comparing surgery ± a fluoropyrimidine and surgery + a fluoropyrimidine ± oxaliplatin. <i>European Journal of Surgical Oncology</i> , <b>2015</b> , 41, 713-23	3.6	87
173	Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1936-1941	10.3	18
172	Microsatellite instability and mutations in BRAF and KRAS are significant predictors of disseminated disease in colon cancer. <i>BMC Cancer</i> , <b>2015</b> , 15, 125	4.8	23
171	Is England closing the international gap in cancer survival?. <i>British Journal of Cancer</i> , <b>2015</b> , 113, 848-60	8.7	75
170	Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. <i>Annals of Oncology</i> , <b>2015</b> , 26, 696-701	10.3	218
169	Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. <i>Annals of Oncology</i> , <b>2015</b> , 26, 463-76	10.3	230
168	Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. <i>British Journal of Surgery</i> , <b>2015</b> , 102, 972-8; discussion 978	5.3	139
167	Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 2470-7	7.5	6
166	Time trends, improvements and national auditing of rectal cancer management over an 18-year period. <i>Colorectal Disease</i> , <b>2015</b> , 17, O168-79	2.1	62
165	High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort. <i>PLoS ONE</i> , <b>2015</b> , 10, e0131046	3.7	64
164	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. <i>Nature Communications</i> , <b>2015</b> , 6, 5751	17.4	44
163	Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. <i>Acta Oncologica</i> , <b>2015</b> , 54, 5-16	3.2	182
162	Toxicity and quality of life data from SCOT: An international phase III randomized (1:1) noninferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3514-3514	2.2	5
161	Prognosis model for overall survival in locally advanced unresectable pancreatic carcinoma: An ancillary study of the LAP 07 trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 235-235	2.2	1
160	Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC): Results of the EXPERT-C trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 581-581	2.2	1
159	C-reactive protein and interleukin-6 as markers of systemic inflammatory response and as prognostic factors for metastatic colorectal cancer. Data from the randomized phase III NORDIC-VII study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3548-3548	2.2	

158	The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. <i>Pharmacogenomics Journal</i> , <b>2014</b> , 14, 424-31	3.5	30
157	EURECCA consensus conference highlights about rectal cancer clinical management: the radiation oncologist's expert review. <i>Radiotherapy and Oncology</i> , <b>2014</b> , 110, 195-8	5.3	53
156	EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 1.e1-1.e34	7.5	274
155	Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2983-93	7.5	45
154	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , <b>2014</b> , 46, 1233-8	36.3	108
153	Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. <i>American Journal of Human Genetics</i> , <b>2014</b> , 95, 462-71	11	74
152	TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. <i>Journal of the National Cancer Institute</i> , <b>2014</b> , 106,	9.7	44
151	Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells. <i>PLoS ONE</i> , <b>2014</b> , 9, e94621	3.7	146
150	Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines. <i>Radiotherapy and Oncology</i> , <b>2014</b> , 113, 352-8	5.3	36
149	Preoperative treatment selection in rectal cancer: a population-based cohort study. <i>European Journal of Surgical Oncology</i> , <b>2014</b> , 40, 1782-8	3.6	16
148	A comprehensive evaluation of the role of genetic variation in follicular lymphoma survival. <i>BMC Medical Genetics</i> , <b>2014</b> , 15, 113	2.1	12
147	Optimal Time Intervals between Pre-Operative Radiotherapy or Chemoradiotherapy and Surgery in Rectal Cancer?. <i>Frontiers in Oncology</i> , <b>2014</b> , 4, 50	5.3	38
146	Adjuvant chemotherapy for rectal cancer. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, e194-5	21.7	4
145	Comparison of ColoPrint risk classification with clinical risk in the prospective PARSC trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3562-3562	2.2	1
144	Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3575-3575	2.2	5
143	Impact of chemoradiotherapy (CRT) on local control and time without treatment in patients with locally advanced pancreatic cancer (LAPC) included in the international phase III LAP 07 study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4001-4001	2.2	15
142	Comparison of ColoPrint risk classification with clinical risk in the prospective PARSC trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 465-465	2.2	1
141	RAS mutations in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC).. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 489-489	2.2	2

140	Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study. <i>PLoS ONE</i> , <b>2014</b> , 9, e87746	3.7	15
139	FCRIIa and FCRIIIa polymorphisms (SNPs) and cetuximab (C) benefit in the EXPERT-C trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3573-3573	2.2	
138	Digitalized multiparametric analyses of tumor stroma for identification of low perivascular PDGFBR expression and low vessel density as independent prognosis markers for stage IV CRC.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e14525-e14525	2.2	
137	Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): An ancillary study of the LAP 07 trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 4024-4024	2.2	
136	Benefit of EGFR-inhibition therapy for metastatic colorectal cancer patients with KRAS-mutated tumors and high plasma TIMP-1 level: Results from the NORDIC VII study.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3590-3590	2.2	
135	Relationship of RAS and TP53 predictive value for cetuximab (C) benefit: Results of the EXPERT-C trial.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 447-447	2.2	
134	Outcome after liver transplantation compared with chemotherapy in colorectal cancer patients with nonresectable liver-only disease.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 531-531	2.2	
133	Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial. <i>BMC Cancer</i> , <b>2013</b> , 13, 279	4.8	203
132	Target Volume Definition in Rectal Cancer: What Is the Best Imaging Modality?. <i>Current Colorectal Cancer Reports</i> , <b>2013</b> , 9, 116-125	1	
131	Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2013</b> , 14, 1208-15	21.7	733
130	Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2013</b> , 24 Suppl 6, vi81-8	10.3	345
129	Adjuvant chemotherapy. <i>European Journal of Cancer, Supplement</i> , <b>2013</b> , 11, 72-9	1.6	1
128	Neo-adjuvant radiotherapy in rectal cancer. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 8489-501	5.6	45
127	Integrated peripheral boost in preoperative radiotherapy for the locally most advanced non-resectable rectal cancer patients. <i>Acta Oncologica</i> , <b>2013</b> , 52, 528-37	3.2	25
126	Patients with rectal cancer receiving adjuvant chemotherapy have an increased survival: a population-based longitudinal study. <i>Annals of Oncology</i> , <b>2013</b> , 24, 160-5	10.3	26
125	Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2013</b> , 24, 2354-60	10.3	49
124	Population-based data from the Swedish Colon Cancer Registry. <i>British Journal of Surgery</i> , <b>2013</b> , 100, 1100-7	5.3	76
123	HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 4006-4006	2.2	8

122	Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, LBA4003-LBA4003	2.2	13
121	Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, LBA4003-LBA4003	2.2	55
120	Plasma levels of TIMP-1 in chemo-naive patients with metastatic colorectal cancer treated with first-line FLOX with or without cetuximab: Results from the Nordic VII Study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 392-392	2.2	
119	Plasma TIMP-1 in patients with metastatic colorectal cancer treated with first-line oxaliplatin-based therapy with or without cetuximab: Results from the Nordic VII study.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, e14710-e14710	2.2	
118	Prognostic significance of tumor stromal and epithelial claudin 2 in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3597-3597	2.2	
117	Tumor perivascular PDGFBR as an independent prognostic factor in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3571-3571	2.2	
116	A Meta-Analysis Of Hodgkin Lymphoma Reveals 19p13.3 (TCF3) As a Novel Susceptibility Loc. <i>Blood</i> , <b>2013</b> , 122, 626-626	2.2	
115	ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. <i>Annals of Oncology</i> , <b>2012</b> , 23, 2479-2516	10.3	984
114	Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1620-7	2.2	293
113	Metastatic colorectal cancer: current treatment and future options for improved survival. Medical approach--present status. <i>Scandinavian Journal of Gastroenterology</i> , <b>2012</b> , 47, 296-314	2.4	49
112	Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future. <i>Uppsala Journal of Medical Sciences</i> , <b>2012</b> , 117, 225-36	2.8	33
111	Lower treatment intensity and poorer survival in metastatic colorectal cancer patients who live alone. <i>British Journal of Cancer</i> , <b>2012</b> , 107, 189-94	8.7	31
110	Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 1755-62	2.2	416
109	EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3508-3508	2.2	20
108	Maintenance therapy with biweekly cetuximab (C) in the first-line treatment of metastatic colorectal cancer (mCRC): The NORDIC 7.5 study (NCT00660582), by the Nordic Colorectal Cancer Biomodulation Group.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3538-3538	2.2	2
107	Prognostic impact of preoperative plasma tissue inhibitor of metalloproteinase 1 (pTIMP-1) in colorectal cancer (CRC) patients (Pts): A pooled analysis of 1,024 stage II/III pts.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3576-3576	2.2	1
106	International experts panel for the development of guidelines for the definition of time to event endpoints in clinical trials (DATECAN project): Results for pancreatic cancer.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 4053-4053	2.2	1
105	ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 8002-8002	2.2	22

104	The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 678-678	2.2	4
103	Plasma concentrations of YKL-40 in chemo-naïve patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3548-3548	2.2	
102	The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer patients using ColoPrint.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, TPS10632-TPS10632	2.2	
101	The impact of TP53 mutation on high-risk rectal cancer patients treated within the EXPERT-C trial, a randomized phase II study of neoadjuvant oxaliplatin/capecitabine (CAPOX) and chemoradiation (CRT) with or without cetuximab.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e14088-e14088	2.2	
100	Which rectal cancers are locally advanced?. <i>Oncology</i> , <b>2012</b> , 26, 743, 746, 751-2	1.8	
99	Survival endpoints in colorectal cancer and the effect of second primary other cancer on disease free survival. <i>BMC Cancer</i> , <b>2011</b> , 11, 438	4.8	40
98	Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2011</b> , 81, 1017-24	4	65
97	Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. <i>Pharmacogenomics Journal</i> , <b>2011</b> , 11, 61-71	3.5	93
96	Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology. <i>Annals of Oncology</i> , <b>2011</b> , 22, 1717-25	10.3	42
95	A new volume of Acta Oncologica. <i>Acta Oncologica</i> , <b>2011</b> , 50, 3-5	3.2	1
94	A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3). <i>Nature Genetics</i> , <b>2010</b> , 42, 1126-1130	36.3	158
93	Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2010</b> , 21 Suppl 5, v82-6	10.3	79
92	Adjuvant chemotherapy in rectal cancer--an issue or a nonissue?. <i>Annals of Oncology</i> , <b>2010</b> , 21, 1739-1744	10.3	18
91	A window of opportunity phase II study of enzastaurin in chemo-naïve patients with asymptomatic metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2010</b> , 21, 1020-6	10.3	21
90	Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. <i>British Journal of Surgery</i> , <b>2010</b> , 97, 580-7	5.3	198
89	Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2009</b> , 20 Suppl 4, 54-6	10.3	44
88	Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. <i>Cancer</i> , <b>2009</b> , 115, 4679-87	6.4	101
87	Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). <i>Radiotherapy and Oncology</i> , <b>2009</b> , 92, 148-63	5.3	229



86	Risk of EBV-Positive Hodgkin Lymphoma Varies Over 30-Fold by HLA Class I Genotype and History of Infectious Mononucleosis.. <i>Blood</i> , <b>2009</b> , 114, 269-269	2.2	
85	Health-related quality of life and distress in cancer patients: results from a large randomised study. <i>British Journal of Cancer</i> , <b>2008</b> , 99, 1975-83	8.7	41
84	Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study. <i>Radiotherapy and Oncology</i> , <b>2008</b> , 87, 343-9	5.3	169
83	Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3687-94	2.2	324
82	A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , <b>2008</b> , 19, 909-14	10.3	35
81	Authors' reply: Late gastrointestinal disorders after rectal cancer surgery with and without preoperative radiation therapy (Br J Surg 2008; 95: 206213). <i>British Journal of Surgery</i> , <b>2008</b> , 95, 803-803 <sup>5.3</sup>		
80	Chemotherapy in addition to preoperative radiotherapy in locally advanced rectal cancer - a systematic overview. <i>Reviews on Recent Clinical Trials</i> , <b>2008</b> , 3, 204-11	1.2	28
79	Late adverse effects of radiation therapy for rectal cancer - a systematic overview. <i>Acta Oncologica</i> , <b>2007</b> , 46, 504-16	3.2	157
78	Individual psychosocial support for breast cancer patients: a randomized study of nurse versus psychologist interventions and standard care. <i>Cancer Nursing</i> , <b>2007</b> , 30, E10-9	2.6	70
77	Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, LBA5-LBA5	2.2	42
76	Authors' reply: Radiological findings do not support lateral residual tumour as a major cause of local recurrence of rectal cancer (Br J Surg 2006; 93: 113219). <i>British Journal of Surgery</i> , <b>2006</b> , 93, 507-507 <sup>5.3</sup>		
75	Late adverse effects of short-course preoperative radiotherapy in rectal cancer. <i>British Journal of Surgery</i> , <b>2006</b> , 93, 1519-25	5.3	161
74	Benefit-risk assessment of irinotecan in advanced colorectal cancer. <i>Drug Safety</i> , <b>2005</b> , 28, 417-33	5.1	21
73	Number of patients potentially eligible for proton therapy. <i>Acta Oncologica</i> , <b>2005</b> , 44, 836-49	3.2	58
72	RESPONSE: Re: Sun Exposure and Mortality From Melanoma. <i>Journal of the National Cancer Institute</i> , <b>2005</b> , 97, 1160-1161	9.7	1
71	Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. <i>Acta Oncologica</i> , <b>2005</b> , 44, 904-912	3.2	87
70	Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 31-8	2.2	68
69	The potential for improved outcome in patients with hepatic metastases from colon cancer: a population-based study. <i>European Journal of Surgical Oncology</i> , <b>2004</b> , 30, 834-41	3.6	36



68	Radiotherapy in rectal cancer. <i>British Medical Bulletin</i> , <b>2002</b> , 64, 141-57	5.4	22
67	Oncology in the nordic countries--the role of Acta Oncologica?. <i>Acta Oncologica</i> , <b>2002</b> , 41, 3-5	3.2	4
66	Swedish Cancer Society Radiation Therapy Research Investigation. <i>Acta Oncologica</i> , <b>2002</b> , 41, 596-603	3.2	9
65	Sensitizing and Protective Substances in Radiation Therapy and Predictive Assays. <i>Acta Oncologica</i> , <b>2002</b> , 41, 615-622	3.2	7
64	Radiation Therapy Through Activation of Stable Nuclides. <i>Acta Oncologica</i> , <b>2002</b> , 41, 629-634	3.2	16
63	Therapy with Radiopharmaceuticals. <i>Acta Oncologica</i> , <b>2002</b> , 41, 623-628	3.2	21
62	Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. <i>Annals of Oncology</i> , <b>2002</b> , 13, 1868-73	10.3	28
61	The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions. <i>Acta Oncologica</i> , <b>2001</b> , 40, 135-54	3.2	21
60	Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. <i>New England Journal of Medicine</i> , <b>2001</b> , 345, 638-46	59.2	3142
59	Non-melanoma skin cancer may be a marker of poor prognosis in patients with non-Hodgkin's lymphoma. <i>International Journal of Cancer</i> , <b>2000</b> , 85, 639-42	7.5	29
58	Implementation of pencil kernel and depth penetration algorithms for treatment planning of proton beams. <i>Physics in Medicine and Biology</i> , <b>2000</b> , 45, 9-27	3.8	78
57	Changing strategy for rectal cancer is associated with improved outcome. <i>British Journal of Surgery</i> , <b>1999</b> , 86, 379-84	5.3	138
56	Is history of squamous-cell skin cancer a marker of poor prognosis in patients with cancer?. <i>Annals of Internal Medicine</i> , <b>1999</b> , 131, 655-9	8	20
55	Perioperative radiotherapy in rectal cancer. <i>Acta Oncologica</i> , <b>1999</b> , 38, 23-32	3.2	33
54	Epstein-Barr virus distribution in Hodgkin's disease in an unselected Swedish population. <i>Acta Oncologica</i> , <b>1999</b> , 38, 425-9	3.2	45
53	Potential gains using high-energy protons for therapy of malignant tumours. <i>Acta Oncologica</i> , <b>1999</b> , 38, 137-45	3.2	34
52	Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease: a prospective study. <i>European Journal of Haematology</i> , <b>1998</b> , 60, 166-71	3.8	11
51	Chemotherapy in the treatment of cancer of the pancreas. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , <b>1998</b> , 5, 235-41		19

50	Preoperative irradiation affects functional results after surgery for rectal cancer: results from a randomized study. <i>Diseases of the Colon and Rectum</i> , <b>1998</b> , 41, 543-9; discussion 549-51	3.1	361
49	Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. <i>European Journal of Cancer</i> , <b>1998</b> , 34, 674-8	7.5	54
48	Evaluation of clinical benefit of chemotherapy in patients with upper gastrointestinal cancer. <i>Acta Oncologica</i> , <b>1998</b> , 37, 651-9	3.2	24
47	The Swedish National Care Programme for Anal Carcinoma--implementation and overall results. <i>Acta Oncologica</i> , <b>1998</b> , 37, 25-32	3.2	20
46	Infradiaphragmatic Hodgkin's disease: the Swedish National Care Programme experience. The Swedish Lymphoma Study Group. <i>European Journal of Haematology</i> , <b>1997</b> , 59, 31-7	3.8	6
45	Improved survival with preoperative radiotherapy in resectable rectal cancer. <i>New England Journal of Medicine</i> , <b>1997</b> , 336, 980-7	59.2	2010
44	[18F] FDG PET in gastric non-Hodgkin's lymphoma. <i>Acta Oncologica</i> , <b>1997</b> , 36, 577-84	3.2	34
43	Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. <i>Annals of Oncology</i> , <b>1997</b> , 8, 163-8	10.3	615
42	Short-term preoperative radiotherapy results in down-staging of rectal cancer: a study of 1316 patients. <i>Radiotherapy and Oncology</i> , <b>1997</b> , 43, 133-7	5.3	135
41	Pregnancy and risk of non-Hodgkin's lymphoma: a prospective study. <i>International Journal of Cancer</i> , <b>1997</b> , 70, 155-8	7.5	32
40	Patients suffering from both Hodgkin's disease and non-Hodgkin's lymphoma: a clinico-pathological and immuno-histochemical population-based study of 32 patients. <i>International Journal of Cancer</i> , <b>1997</b> , 71, 510-6	7.5	22
39	Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin's disease. <i>International Journal of Cancer</i> , <b>1997</b> , 72, 394-7	7.5	29
38	Patients suffering from both Hodgkin's disease and non-Hodgkin's lymphoma: A clinico-pathological and immuno-histochemical population-based study of 32 patients <b>1997</b> , 71, 510		1
37	Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. <i>Annals of Oncology</i> , <b>1996</b> , 7, 593-600	10.3	572
36	Ultraviolet light and non-Hodgkin's lymphoma. <i>Acta Oncologica</i> , <b>1996</b> , 35, 655-7	3.2	21
35	Anxiety, depression and worry in gastrointestinal cancer patients attending medical follow-up control visits. <i>Acta Oncologica</i> , <b>1996</b> , 35, 411-6	3.2	19
34	Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for non-Hodgkin's lymphomas: a Swedish national prospective study. Swedish Lymphoma Study Group. <i>Acta Oncologica</i> , <b>1996</b> , 35, 165-70	3.2	11
33	Different intravenous administration techniques for 5-fluorouracil. Pharmacokinetics and pharmacodynamic effects. <i>Acta Oncologica</i> , <b>1996</b> , 35, 207-12	3.2	32

32	Maternal and perinatal risk factors for childhood brain tumors (Sweden). <i>Cancer Causes and Control</i> , <b>1996</b> , 7, 437-48	2.8	79
31	Treatment of Hodgkin's disease: the Swedish National Care Programme experience. <i>Leukemia and Lymphoma</i> , <b>1996</b> , 21, 71-8	1.9	31
30	Radiotherapy in addition to radical surgery in rectal cancer. <i>Acta Oncologica</i> , <b>1995</b> , 34, 565-70	3.2	16
29	Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. <i>Annals of Oncology</i> , <b>1995</b> , 6, 267-74	10.3	109
28	Selective sensitivity of solid tumors to suramin in primary cultures of tumor cells from patients. <i>International Journal of Cancer</i> , <b>1995</b> , 63, 356-60	7.5	9
27	A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT <sub>3</sub> receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. <i>Cancer</i> , <b>1994</b> , 73, 445-54	6.4	33
26	Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. <i>Cancer</i> , <b>1994</b> , 73, 556-62	6.4	114
25	Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. <i>International Journal of Cancer</i> , <b>1994</b> , 56, 715-20	7.5	69
24	Diagnostics of malignant lymphomas with ultrasound guided 1.2 mm biopsy-gun. <i>Acta Oncologica</i> , <b>1994</b> , 33, 33-7	3.2	10
23	Treatment of early and intermediate stages of supradiaphragmatic Hodgkin's disease: the Swedish National Care Programme experience. Swedish Lymphoma Study Group. <i>Annals of Oncology</i> , <b>1994</b> , 5, 809-16	10.3	18
22	Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer <b>1994</b> , 73, 556		1
21	Radioimmunolocalization of hepatic metastases and subcutaneous xenografts from a human colonic cancer in the nude rat. Aspects of tumour implantation site and mode of antibody administration. <i>Acta Oncologica</i> , <b>1993</b> , 32, 877-85	3.2	3
20	A Comprehensive Cancer Care Project to Improve the Overall Situation of Patients Receiving Intensive Chemotherapy. <i>Journal of Psychosocial Oncology</i> , <b>1993</b> , 11, 17-40	2.8	16
19	Biochemical modulation of 5-fluorouracil: a randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. <i>Annals of Oncology</i> , <b>1993</b> , 4, 235-40	10.3	55
18	Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. <i>Hematological Oncology</i> , <b>1993</b> , 11, 187-93	1.3	71
17	Pre-chemotherapy nervousness as a marker for anticipatory nausea: A case of a non-causal predictor. <i>Psycho-Oncology</i> , <b>1993</b> , 2, 33-41	3.9	3
16	Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects. <i>Diseases of the Colon and Rectum</i> , <b>1993</b> , 36, 564-72	3.1	395
15	The value of adjuvant therapy after radical surgery for colorectal cancer. <i>Annals of Medicine</i> , <b>1992</b> , 24, 9-14	1.5	6

14	Improved care of patients with small cell lung cancer. Nutritional and quality of life aspects. <i>Acta Oncologica</i> , <b>1992</b> , 31, 823-31	3.2	13
13	General condition of asymptomatic patients with advanced colorectal cancer receiving palliative chemotherapy. A longitudinal study. <i>Acta Oncologica</i> , <b>1992</b> , 31, 645-51	3.2	30
12	Lymphoma incidence in a Swedish county during 1969-1987. <i>Acta Oncologica</i> , <b>1992</b> , 31, 275-82	3.2	29
11	A comparative study of proliferation-associated parameters in B-cell non-Hodgkin lymphoma. <i>Hematological Oncology</i> , <b>1991</b> , 9, 287-98	1.3	11
10	Prognostic significance of flow cytometry studies in B-cell non-Hodgkin lymphoma. <i>Hematological Oncology</i> , <b>1990</b> , 8, 1-12	1.3	42
9	Primarily asymptomatic low-grade non-Hodgkin lymphomas: prediction of symptom-free survival and total survival. <i>European Journal of Haematology</i> , <b>1989</b> , 43, 332-8	3.8	13
8	Immunophenotype analysis of B-CLL lymphoma and immunocytoma. <i>Apmis</i> , <b>1989</b> , 97, 1025-32	3.4	5
7	Prognostic relevance of serum-markers in relation to histopathology, stage and initial symptoms in advanced low-grade non-Hodgkin lymphomas. <i>European Journal of Haematology</i> , <b>1988</b> , 40, 289-98	3.8	20
6	Extracellular matrices in multicellular spheroids of human glioma origin: increased incorporation of proteoglycans and fibronectin as compared to monolayer cultures. <i>Apmis</i> , <b>1988</b> , 96, 433-44	3.4	37
5	Cytostatic drug therapy in disseminated colorectal cancer. <i>Scandinavian Journal of Gastroenterology</i> , <b>1988</b> , 149, 181-9	2.4	2
4	A clinical study of CA-50 as a tumour marker for monitoring of colorectal cancer. <i>Medical Oncology and Tumor Pharmacotherapy</i> , <b>1988</b> , 5, 165-71		6
3	Radiation therapy in upper GI tract tumours. <i>Acta Chirurgica Scandinavica Supplementum</i> , <b>1988</b> , 541, 32-8		
2	DNA content in carcinoma of the rectum and rectosigmoid. <i>Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section A, Pathology</i> , <b>1985</b> , 93, 277-84		1
1	Local recurrences after surgical treatment for rectal carcinoma. <i>Acta Chirurgica Scandinavica</i> , <b>1984</b> , 150, 331-5		89